MedMira Partner Vitest Signs Exclusive Agreement with Red Cross Nigeria to Provide 2 Million Rapid HIV Tests

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions, today announced that the Company's strategic business development partner for Africa, Vitest AG, has signed an exclusive agreement with the Nigerian Red Cross Society to provide two million MedMira rapid HIV tests under private label. This two million test order is the first part of a broader, long term partnership between Vitest and the Red Cross to enhance public awareness of HIV and testing programs within Nigeria.

"Our exclusive contract with the Red Cross is a milestone in our efforts to create long term partnerships in Africa. The Red Cross in Nigeria has been conducting a rigorous evaluation of the quality, ease of use, and technical support associated with the product over the last six months.

Virtual Radiologic to Be Acquired by Providence Equity Partners

Virtual Radiologic Corporation (NASDAQ: VRAD), a national radiology practice and a leader in the development of radiologist workflow technology, and Providence Equity Partners, a leading global private equity firm that manages over $22 billion in equity capital, today announced that they have entered into a definitive agreement under which Providence will acquire all of the outstanding common stock of vRad for $17.25 per share in cash. The offer price represents a premium of 41.7 percent over the 30-day average closing stock price of $12.18 as of May 14, 2010, and a premium of 54.9 percent over the three month average closing stock price of $11.13. Based on the per share consideration, the transaction is valued at approximately $294 million.

Response Genetics Signs Agreement with GlaxoSmithKline to Provide Proprietary BRAF Mutational Analysis Technology

Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline (“GSK”). Under the terms of the agreement, GSK gains certain rights to Response Genetics’ proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones. Further financial details were not disclosed.

The BRAF gene encodes B-Raf proto-oncogene serine/threonine-protein kinase (B-raf), a protein involved in cell signaling and cellular growth and differentiation. Specific genetic mutations have been correlated with the development of certain forms of cancer.

Sequenom Introduces the MassARRAY Analyzer 4 System

Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of its next-generation mass spectrometry system - the MassARRAY Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance. With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases.

The MassARRAY Analyzer 4 system will initially be offered to research-use-only (RUO) laboratories, and subject to FDA clearance will be released to CLIA-certified laboratories for the generation and implementation of laboratory-developed tests.